
VBI Vaccines Investor Relations Material
Latest events

Fireside Chat
VBI Vaccines

Q1 2024
15 May, 2024

Q4 2023
16 Apr, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from VBI Vaccines Inc
Access all reports
VBI Vaccines Inc., also known as Variation Biotechnologies Inc., is a biopharmaceutical company focused on the development and commercialization of vaccines for infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a commercialized hepatitis B vaccine, and has several vaccine candidates in various stages of development. These include treatments for hepatitis B, glioblastoma, cytomegalovirus, and Zika virus, along with multiple coronavirus vaccine candidates. VBI Vaccines has significant collaborations with entities like GlaxoSmithKline, the National Research Council of Canada, and the Coalition for Epidemic Preparedness Innovations. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
VBIV
Country
🇺🇸 United States